Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22014104 | 0.94 | HRH3 (0.56) | HRH3SIGMAR1HDAC1HDAC4KCNH2 | |
| SCHEMBL22014091 | 0.91 | SIGMAR1 (0.64) | SIGMAR1HDAC1HDAC4KCNH2ALDH1A1 | |
| SCHEMBL22014095 | 0.88 | FAAH (0.55) | HRH3SIGMAR1HDAC1HDAC4KCNH2 | |
| SCHEMBL22014096 | 0.85 | SIGMAR1 (0.49) | SIGMAR1ALDH1A1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL22014485 | 0.84 | HRH3 (0.47) | HRH3HRH4 | |
| SCHEMBL22014099 | 0.81 | MPO (0.53) | SIGMAR1ALDH1A1LMNAPOLBKDM4E | |
| SCHEMBL23532238 | 0.80 | MAPT (0.52) | ALDH1A1POLBKDM4E | |
| SCHEMBL3966649 | 0.80 | MAPT (0.52) | ALDH1A1POLBKDM4E | |
| SCHEMBL336769 | 0.80 | MAPT (0.52) | ALDH1A1POLBKDM4E | |
| SCHEMBL22355488 | 0.79 | SIGMAR1 (0.49) | SIGMAR1HDAC1HDAC4KCNH2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11344635-B2 | Compounds for use as iron (III) MRI contrast agents containing anionic pendents and ancillary groups | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2022-05-31 | — | — | US | disclosed |
| WO-2020102820-A1 | COMPOUNDS FOR USE AS IRON (III) MRI CONTRAST AGENTS CONTAINING ANIONIC PENDENTS AND ANCILLARY GROUPS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344635-B2 | Compounds for use as iron (III) MRI contrast agents containing anionic pendents and ancillary groups | SLC40A1, TAC3, ABCB7 | HRH3 2695/4885SIGMAR1 1907/4885HDAC1 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.